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PURPOSE. The present study was designed to investigate the role of myofibroblast trans-
differentiation and the conjunctival renin–angiotensin system (RAS) in the pathogenesis
of graft-versus-host disease (GVHD)–associated conjunctival fibrosis.
METHODS. A mouse model of major histocompatibility-matched allogeneic transplantation
was used to induce GVHD, with male B10.D2 mice as donors and female BALB/c mice
as recipients. Male BALB/c to female BALB/c syngeneic transplantation was used as
control. Y chromosome staining in the spleen cells obtained from female recipient mice
was used to confirm engraftment. The phenol red thread test and fluorescein staining
were used to quantify tears and corneal keratopathy. Eyes were harvested at 4 and 8
weeks after the transplant for alpha-smooth muscle actin (α-SMA), angiotensinogen, and
angiotensin-converting enzyme (ACE) immunostaining. Conjunctiva was harvested for
gene expression quantification of α-SMA, angiotensinogen, and ACE.
RESULTS. More than 80% of the spleen cells in the recipient mice were chromosome Y
positive, thus conforming successful engraftment. A significant decrease in tear secre-
tion and a marked increase in corneal keratopathy score after allogeneic transplantation
indicated the onset of ocular GVHD in these mice. A significant increase in α-SMA gene
expression and the presence of a large number of α-SMA–positive cells was noted in the
bulbar orbital conjunctiva of mice after allogeneic transplantation. Allogenic transplan-
tation also caused a significant increase in the gene expression and protein expression
of angiotensinogen and ACE in the subconjunctival eyelid area.
CONCLUSIONS. Results of the present study demonstrate that GVHD-associated conjunctival
fibrosis is accompanied by myofibroblast formation and activation of the local conjunc-
tival RAS.
Keywords: GVHD, conjunctival fibrosis, conjunctival RAS, myofibroblasts
A llogeneic bone marrow transplantation is a stan-dard treatment for many hematologic malignan-
cies, hemoglobinopathies, and immunodeficiency diseases.
However, graft-versus-host disease (GVHD) remains a chal-
lenging complication of allogeneic bone marrow transplan-
tation. It is an immune-mediated condition that causes
damage to many organs, including eyes, with 60% to 90% of
patients with GVHD showing ocular complications.1,2 Eyes
are affected in both acute and chronic GVHD, although
ocular involvement is more common in patients with chronic
GVHD. Acute GVHD can cause photophobia, hyperemia,
conjunctivitis, lagophthalmos, and corneal ulceration,2–5
whereas chronic GVHD is characterized by severe ocular
surface damage, resulting in dry eye, keratinization, epithe-
lial thinning, squamous metaplasia, corneal ulceration, and
meibomian gland atrophy.2,6
Conjunctiva is also significantly affected in patients with
chronic GVHD, with such manifestations as pseudomem-
branous conjunctivitis, symblepharon, and fornix shorten-
ing.2,4 Additionally, patients with GVHD show a white scar
under their bulbar conjunctiva suggestive of subepithelial
conjunctival fibrosis.7,8 Injury to conjunctival tissue caused
by a chronic inflammatory response due to GVHD can initi-
ate a wound-healing response. An excessive wound-healing
response may lead to aberrant extracellular matrix synthe-
sis, thus resulting in conjunctival fibrosis. Myofibroblasts are
contractile, metabolically active cells that synthesize large
quantities of extracellular matrix proteins and play a key
role in fibrosis.9–11 Myofibroblasts can form by transdiffer-
entiation of a variety of cells such as resident fibroblasts,
mesenchymal cells, and circulating fibrocytes.9–11 Conjunc-
tiva is a connective tissue containing a significant number of
fibroblasts, and the presence of donor-origin fibrocytes has
also been demonstrated in the eyes of patients with GVHD.12
Conjunctival tissue has been shown to express compo-
nents of the local renin–angiotensin system (RAS), including
Copyright 2021 The Authors
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renin, angiotensinogen, angiotensin-converting enzyme
(ACE), and angiotensin II type 1 (AT1) receptor.13–17 As
for many other organs, angiotensin II, the end effector of
the RAS pathway, has been implicated as playing a role in
conjunctival fibrosis.18,19 Components of the RAS are upreg-
ulated after conjunctival injury.18 Angiotensin II has been
shown to cause transdifferentiation of Tenon’s fibroblasts to
myofibroblasts.19 Profibrotic cytokines such as transforming
growth factor-beta (TGF-β), platelet-derived growth factor
(PDGF), and connective tissue growth factor (CTGF) that
are released by immune cells in GVHD can serve as the
initial trigger for fibroblast transdifferentiation to myofibrob-
lasts.20,21 However, upregulation of the RAS and cross-talk
between profibrotic cytokines, especially TGF-β and the
RAS, has been shown to amplify and perpetuate fibrosis
in non-ocular organs and could be a potential mechanism
that may contribute to conjunctival fibrosis.22,23 The present
study was designed to investigate the role of myofibroblast
transdifferentiation and the conjunctival RAS in the patho-
genesis of GVHD-associated conjunctival fibrosis.
METHODS
Bone Marrow Transplantation
The animal protocol was approved by Institutional Animal
Care and Use Committee of Chapman University (approval
#2019-06). All animal experiments were conducted in accor-
dance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. A mouse model of
major major histocompatibility complex (MHC)-matched
and minor MHC-mismatched mice was used to induce
GVHD.24–26 Eight-week-old male B10.D2 mice (The Jack-
son Laboratory, Bar Harbor, ME, USA) having homozy-
gous MHC haplotype d/d were used as donors, and 10-
week-old female BALB/c mice (Charles River Laboratories,
Wilmington, MA, USA) also having homozygous haplotype
d/d were used as recipients. The control group underwent
syngeneic transplantation, where donors were 8-week-old
male BALB/c mice and recipients were 10-week-old female
BALB/c mice. The femurs and spleen cells were harvested
from the donor mice, as described in our earlier publi-
cation.27 Recipient female BALB/c mice were exposed to
700-cGy irradiation using an x-ray irradiator (RS2000 Series
Biological Irradiator; Rad Source Technologies, Suwanee,
GA, USA). After 6 hours, the irradiated recipient female
BALB/c mice were injected with 2 × 106 spleen cells
and 1 × 106 bone marrow cells. The mice were fed with
a diet gel (ClearH2O, Portland, ME, USA), were housed
in sterile cages, and received sulfatrim (0.672 mg/mL)
in their drinking water for 2 weeks after the transplant. At
4 and 8 weeks after transplantation, the animals were euth-
anized by CO2 administration for the collection of ocular
tissue. The study design included two different groups of
mice: (1) the control group, which included BALB/c female
mice (n = 9) that received syngeneic bone marrow and
spleen cell transplantation from male BALB/c mice; and (2)
the ocular GVHD group, which included female BALB/c
mice (n =12) that received allogeneic bone marrow and
spleen cell transplantation from male B10.D2 mice.
Monitoring of Engraftment
The presence of Y chromosome in the spleen cells of female
recipient mice was used to track engraftment by male donor
marrow. A fluorescent paint probe was used to stain chro-
mosome Y by fluorescent in situ hybridization (FISH) using
a commercially available kit (Empire Genomics, Buffalo, NY,
USA).Mice were also monitored for systemic signs of chronic
GVHD, such as loss of body weight and body hair.
Tear Quantification
Tear secretion was quantified by phenol red thread (FCI
Ophthalmics, Pembroke, MA, USA) which is pH sensitive
and changes from yellow to red upon wetting by tears. The
thread was placed in the temporal side of the lower eyelid
for 1 minute. The length of color change was measured in
millimeters and converted to volume using a standard plot.
A standard curve was plotted by wetting the thread with
known volume of artificial tears and measuring the length
of the wetted phenol red thread. Due to the small amount
of tear film volume in the mouse eyes, the phenol red
thread test typically requires longer time to obtain consis-
tent values, accordingly a 1-minute duration for the phenol
red thread test was used. Tear volume was quantified before
the allogeneic and syngeneic transplantation (baseline) and
at weeks 2, 4, 6, and 8 after the transplantation.27
Fluorescein Staining
Mice were anesthetized by intraperitoneal injection of
ketamine (80 mg/kg) and xylazine (5 mg/kg). A 2-μL
sterile solution of 0.5% fluorescein was applied to the
mouse eye for 60 seconds. The eyes were washed with
200 μL phosphate-buffered saline (PBS), and imaging was
performed under a cobalt filter with a slit lamp (SL-17;
Kowa USA, Torrance, CA, USA) using a digital camera. The
captured corneal images were divided into four hypotheti-
cal quadrants for scoring the keratopathy using a previously
published method.27,28 Each quadrant was scored as follows:
no staining = 0; slightly punctate staining, less than 30 spots
= 1; punctate staining, more than 30 spots but not diffuse =
2; diffuse staining but no positive plaque = 3; and positive
fluorescein plaque = 4. The scores of each quadrant were
added to arrive at a final grade (total maximum possible
score = 16).
Tissue Harvesting and Cryosectioning
Eyes along with the eyelids were harvested from eutha-
nized animals. The tissue was fixed in 4% paraformalde-
hyde overnight 15% and then 30% or 15% followed by
30% sucrose. The tissue was embedded in optimal cutting
temperature compound using a 2-methylbutane bath cooled
over liquid nitrogen. To perform immunofluorescent stain-
ing, a cryostat (CM 1860; Leica Microsystems, Wetzlar,
Germany) was used to cut sagittal sections from the frozen
tissue at a thickness of 8 μm.
Immunofluorescence Staining for Alpha-Smooth
Muscle Actin, Angiotensinogen, ACE, AT1
Receptor, and Tomato Lectin Staining
Slides containing 8-μm-thick sagittal sections of the eye and
eyelid were rinsed in PBS and blocked with PBS solution
containing 2% bovine serum albumin for 30 minutes. The
tissue sections were then incubated with primary antibodies
for alpha-smooth muscle actin (α-SMA) (1:100 dilution; Invit-
rogen, Carlsbad, CA, USA), angiotensinogen (1:50 dilution;
R&D Systems, Minneapolis, MN, USA), ACE (1:25 dilution;
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TABLE. Sequence of Forward and Reverse Primers Used for Real-Time PCR
Gene Reverse Primer Forward Primer
Angiotensinogen 5′-CAA GTT GAT CTT CCA CCC TGT C-3′ 5′-TCC CAC GCT CTC TGG ATT TA-3′
ACE 5′-TTG CTG CCC TCT ATG GTA ATG-3′ 5′-GAC AGG TTC GTG GAA GAG TAT G-3′
α-SMA 5′-GGC AGT AGT CAC GAA GGA ATA G-3′ 5′-CCA TCA TGC GTC TGG ACT T-3′
β-Actin 5′-CCA AGA AGG AAG GCT GGA AA-3′ 5′-CTC CCT GGA GAA GAG CTA TGA-3′
R&D Systems), AT1 receptors (1:50 dilution; Novus Biologi-
cals, Littleton, CO, USA), and DyLight 594 conjugated tomato
lectin (1:200 dilution; Vector Laboratories, Burlingame, CA,
USA) for 90 minutes. The slides were washed with PBS three
times and incubated with Alexa Fluor 488 or Alexa Fluor
647 conjugated secondary antibody (1:500 dilution; Abcam,
Cambridge, UK) for 60 minutes. The nuclei were stained
with 4′,6-diamidino-2-phenylindole (DAPI). The slides were
imaged using a confocal microscope (Nikon, Melville, NY,
USA). The number of nuclei showing α-SMA staining and
the percent fraction of area showing angiotensinogen and
ACE staining were quantified using Image J (National Insti-
tutes of Health, Bethesda, MD, USA).
RNA Isolation, cDNA Preparation, and Gene
Expression Quantification
Iris scissors and fine pointed forceps were used to remove
the entire sheet of bulbar conjunctival tissue from the euth-
anized animals’ eyes at the end of 4 and 8 weeks after
transplantation. The mRNA was extracted using the RNeasy
Mini Kit (QIAGEN, Valencia, CA, USA). The RNA concen-
tration was quantified using a NanoDrop spectrophotome-
ter (Thermo Fisher Scientific, Waltham, MA, USA). The yield
was between 37 and 53 ng/μL. The mRNA was immediately
reverse transcribed to cDNA using a commercially available
kit (SuperScript III First-Strand Synthesis System; Thermo
Fisher Scientific). The cDNA was used to quantify α-SMA,
angiotensinogen, and ACE gene expressions by real-time
PCR. A 20-μL reaction mixture containing 2 μL of cDNA, 2 μL
each of 200-nM forward primer and reverse primer (Table),
and 10 μL of 2× SYBR Green Supermix (Bio-Rad Laborato-
ries, Hercules, CA, USA) was run at a universal cycle (95°C
for 10 minutes, 40 cycles at 95°C for 15 seconds, and 55°C
for 60 seconds) in a thermocycler (CFX96 Touch thermocy-
cler; Bio-Rad Laboratories). β-Actin was used as the house-
keeping gene. The relative change in gene expression was
calculated using the Ct method.
Statistics
The data are presented as mean ± standard error of the
mean. Statistical analysis was performed using Prism 8
(GraphPad Software, San Diego, CA, USA). The data were
analyzed using two-way analysis of variance (ANOVA) for
body weight, tear film volume, and corneal keratopathy and
one-way ANOVA for α-SMA, angiotensinogen, and ACE gene
and protein expression, followed by Dunnett’s post hoc test.
P < 0.05 was considered statistically significant.
RESULTS
Characterization of GVHD and Allogenic
Transplantation
Mice who received allogeneic transplantation began to
exhibit signs of GVHD at around 4 weeks, including a signif-
icantly lower body weight (Fig. 1A), signs of skin sclero-
derma, and loss of body hair (Fig. 1B). Interestingly, a sharp
decrease in body weight was observed up to the initial
2 weeks after transplantation in both groups that received
either allogeneic or syngeneic transplantation. This early
decrease in body weight noted in both the groups can
be likely attributed to the irradiation stress (Fig. 1A). Both
groups regained body weight by week 4; however, the regain
of body weight was significantly lower in mice with the
allogeneic transplant compared with mice that received the
syngeneic transplant. Furthermore, after this initial recov-
ery, mice with the allogeneic transplant did not show any
further gain, and their body weight plateaued, suggesting
the onset of systemic GVHD. In contrast, mice that received
the syngeneic transplant continued to show an upward trend
with a notable increase in body weight (Fig. 1A).
Because the donor mice in our model were male and the
recipient mice were female, we used Y chromosome stain-
ing to confirm the successful engraftment of donor-origin
marrow cells. Figure 1C shows FISH staining for Y chro-
mosome in the spleen cells obtained from recipient female
mice at 4 weeks after allogeneic transplantation. Quantifi-
cation of spleen cells from five different animals indicated
that an average of 80% of the spleen cells showed Y chromo-
some staining, thus confirming the successful engraftment of
recipient mice by cells originating from male donor marrow.
FIGURE 1. (A) Body weight of mice before (baseline) and at vari-
ous time points after syngeneic and allogeneic transplantation. A
significant decrease (*P < 0.05) in body weight was observed in
mice who received allogeneic transplantation compared with mice
receiving syngeneic transplantation. (B) Representative photograph
showing signs of sclerodermatous skin lesions and hair loss in mice
who received allogeneic transplantation. Spleen cells of recipient
(female) mice showing Y chromosome staining confirm successful
engraftment of the donor (male) graft.
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FIGURE 2. Tear film volume in mice before (baseline) and at vari-
ous time points after syngeneic and allogeneic transplantation. A
significant decrease (*P < 0.05) in tear film volume was observed in
mice who received allogeneic transplantation compared with mice
receiving syngeneic transplantation.
Clinical Signs of Ocular GVHD
The mice who received allogeneic transplantation showed
signs of ocular GVHD that included a decrease in tear film
and onset of corneal keratopathy. Figure 2 shows the time-
dependent changes in tear film volume in the mice that
received either syngeneic or allogeneic transplantation. The
two groups had average tear volumes of 153 nL and 137nL
at baseline prior to syngeneic or allogeneic transplantation,
respectively. As for body weight, both groups showed a
decrease in tear film volume at 2 weeks after the transplant
which could be attributed to irradiation stress-related physi-
ological changes. However, mice that received the allogeneic
transplant continued to show a further decline in tear film
volume at weeks 6 and 8 after the initial slight regain at week
4. The tear volume in the mice with allogenic transplantation
FIGURE 4. Gene expression quantification of α-SMA in conjunctival
homogenates obtained from mice at 8 weeks after syngeneic trans-
plantation (control) and at 4 weeks and 8 weeks after allogeneic
transplantation (GVHD). A significant increase (*P < 0.05) in α-SMA
gene expression was noted in conjunctival homogenates obtained
from mice after allogeneic transplantation compared with tissues
obtained from the mice that received syngeneic transplantation.
was significantly less compared with mice that received the
syngeneic transplant.
Figure 3A shows representative fluorescein-stained image
of mice eyes that received syngeneic or allogeneic transplan-
tation. The corneas of mice that received allogenic trans-
plantation showed punctate staining at week 4 and even
plaques after week 8. Quantification of corneal keratopathy
showed that both groups had a mean score of 2 at the base-
line (Fig. 3B). Mice that received allogenic transplantation
FIGURE 3. (A) Representative fluorescein-stained images of corneas at 8 weeks after syngeneic transplantation (control) and at 4 weeks and
8 weeks after allogeneic transplantation (GVHD). (B) Quantification of fluorescein staining showed significant corneal keratopathy (*P <
0.05) compared with syngeneic transplantation and before transplantation at 4 and 8 weeks after allogeneic transplantation.
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FIGURE 5. (A) Representative confocal images showing immunofluorescent staining (green) for α-SMA in eyelid tissue sections obtained
from mice at 8 weeks after syngeneic transplantation (control) and at 4 weeks and 8 weeks after allogeneic transplantation (GVHD). Nuclei
are stained blue with DAPI. (B) Graph shows quantification of α-SMA–stained nuclei in images obtained from five different slides each from
five mice. A significant increase (*P < 0.05) in α-SMA–stained nuclei was observed in tissues obtained from mice at 4 weeks and 8 weeks
after allogeneic transplantation compared with tissues obtained from mice that received syngeneic transplantation.
showed a significant increase in mean corneal keratopathic
score to 6 and 9.3 at 4 weeks and 8 weeks, respectively. The
syngeneic mice also showed a slight increase in keratopathy
score to 3.6 at week 8 (Fig. 3B), possibly due to aging or
irradiation, as radiation stress has been previously shown to
cause corneal keratopathy.29,30
Presence of Conjunctival Myofibroblasts in Ocular
GVHD
The presence of myofibroblasts is a hallmark feature of
fibrosis. Myofibroblasts express high levels of intracellu-
lar bundles of α-SMA. Therefore, to test whether ocular
GVHD causes conjunctival fibrosis due to myofibroblast
formation, we used gene expression to quantify α-SMA and
performed α-SMA immunostaining to detect the localiza-
tion of myofibroblasts. A 2.7-fold increase (P < 0.05) and a
2.02-fold increase in α-SMA gene expression were observed
in the conjunctival tissue obtained from mice at 4 weeks
and 8 weeks after allogeneic transplantation, respectively
(Fig. 4). Furthermore, immunostaining detected the presence
of a large number of α-SMA–positive myofibroblasts in the
bulbar orbital conjunctiva of mice at 4 and 8 weeks after
allogeneic transplantation (Fig. 5A). In contrast, no myofi-
broblasts could be detected in the tissue sections obtained
from mice that received syngeneic transplantation (Fig. 5A).
Quantification of the number of nuclei showed an aver-
age of 1079 α-SMA–positive nuclei at 4 weeks and 978 α-
SMA–positive nuclei at 8 weeks after allogeneic transplan-
tation compared with around 250 α-SMA–positive nuclei
in mice that received the syngeneic transplant (Fig. 5B).
Eyelids are vascular tissues, and α-SMA can stain the smooth
muscle actin of the vasculature. To exclude the possibility
that the α-SMA staining noted in the bulbar subconjuncti-
val space was due to the presence of vascular tissue, we
performed double-staining of α-SMA with lectin (Supple-
mentary Figure). As is evident from the double staining,
lectin extensively stained the vasculature in the eyelid tissue.
A double staining of lectin and α-SMA showed the typical
shape of blood vessel tissue; however, α-SMA staining in
the bulbar subconjunctival space did not show any lectin
staining, confirming that this α-SMA staining was due to the
presence of myofibroblasts (Supplementary Figure). As is
evident from the nuclear staining of eyelid tissue in Figure
5A, a notable shortening of the eyelid can be seen in the
histology sections obtained from the GVHD mice at 8 weeks
after allogeneic transplantation. Therefore, we decided to
quantify the eyelid length in the tissue sections obtained
from the control and GVHD mice. Our data indicate that
the length of the upper eyelid tissue sections of the control
mice that received the syngeneic transplant was 1261.5 ±
26.4 μm compared with 791.5 ± 64.7 μm in the GVHD mice
at 8 weeks after allogeneic transplantation. Thus, the data
demonstrate that GVHD caused upper eyelid shortening in
this study.
Ocular GVHD and Conjunctival RAS Activation
To test whether conjunctival fibrosis was accompanied
by activation of the local RAS, we quantified the gene
expression of angiotensinogen and ACE. We also detected
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FIGURE 6. Gene expression quantification of angiotensinogen and ACE in conjunctival homogenates obtained from mice at 8 weeks after
syngeneic transplantation (control) and at 4 weeks and 8 weeks after allogeneic transplantation (GVHD). A significant increase (*P < 0.05)
in angiotensinogen and ACE gene expression was noted in conjunctival homogenates obtained from mice after allogeneic transplantation
compared with tissues obtained from mice that received syngeneic transplantation.
FIGURE 7. (A) Representative confocal images showing immunofluorescent staining (green) for angiotensinogen in the eyelid tissue sections
obtained from mice at 8 weeks after syngeneic transplantation (control) and at 4 weeks and 8 weeks after allogeneic transplantation (GVHD).
Nuclei are stained blue with DAPI. (B) Graph shows quantification of the angiotensinogen-stained area (calculated as a fraction of total eyelid
area) using images obtained from five different slides each from five mice. A significant increase (*P < 0.05) in angiotensinogen-stained area
was observed in tissues obtained from mice at 4 weeks and 8 weeks after allogeneic transplantation compared with tissues obtained from
mice that received syngeneic transplantation.
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FIGURE 8. (A) Representative confocal images showing immunofluorescent staining (red) for ACE in eyelid tissue sections obtained from
mice at 8 weeks after syngeneic transplantation (control) and at 4 weeks and 8 weeks after allogeneic transplantation (GVHD). Nuclei are
stained blue with DAPI. (B) Graph shows quantification of the angiotensinogen-stained area (calculated as a fraction of total eyelid area)
using images obtained from five different slides each from five mice. An increase in ACE-stained area was observed in tissues obtained from
mice at 4 weeks (*P < 0.05) and 8 weeks after allogeneic transplantation compared with tissues obtained from mice that received syngeneic
transplantation.
FIGURE 9. Representative confocal images showing immunofluorescent staining for AT1 receptors (red) and α-SMA (green) in the eyelid
tissue sections obtained from mice after syngeneic transplantation (control) and allogeneic transplantation (GVHD). Nuclei are stained blue
with DAPI. Arrows in the merge image show colocalization of AT1 receptors with α-SMA.
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angiotensinogen and ACE localization by performing
immunostaining. A statistically significant 1.4-fold increase
(P < 0.05) in the gene expression of angiotensinogen and a
2-fold increase (P < 0.05) in the gene expression of ACE was
observed in the conjunctival tissue obtained from mice at
4 weeks after allogeneic transplantation. By the 8-week time
point, this increase in angiotensinogen and ACE returned to
baseline (Fig. 6).
Immunostaining detected a large area under the bulbar
conjunctiva that was intensely stained for angiotensinogen
(Fig. 7A) and ACE (Fig. 8A) at 4 weeks after allogeneic trans-
plantation. On the other hand, angiotensinogen and ACE
staining was barely detectable in the eyelids of mice that
received the syngeneic transplant. Quantification of percent-
age of stained area as a fraction of the total eyelid for
angiotensinogen showed only a 4% stained area in mice
that received syngeneic transplantation but 37% stained area
(P < 0.05) and 22% stained area (P < 0.05) in mice at 4
weeks and 8 weeks after allogeneic transplantation, respec-
tively (Fig. 7B). Similarly,<0.4% area showed ACE staining in
mice that received syngeneic transplantation compared with
2% area (P < 0.05) and 1.5% area at 4 weeks and 8 weeks,
respectively, in mice that received allogenic transplantation
(Fig. 8B).
Finally, we examined whether AT1 receptors were
expressed in the mouse conjunctiva and if there was a colo-
calization of AT1 receptors with the α-SMA staining. As
is evident from the immunostaining images, AT1 receptor
expression was detected in the conjunctival epithelium and
subconjunctival space of tissue sections obtained from the
control mice that received syngeneic transplantation (Fig. 9).
Furthermore, a substantial increase in AT1 receptor expres-
sion was observed in the tissue sections obtained from
GVHD mice that received allogeneic transplantation. It is
worthwhile to note that AT1 receptor staining colocalized
with the α-SMA staining in the bulbar conjunctiva around
the fornix. Therefore, our data indicate that the conjunctival
myofibroblasts expressed AT1 receptors (Fig. 9, merge).
DISCUSSION
Fibrosis is one of the key features of chronic GVHD and
affects many organs, including lungs, skin, and gastrointesti-
nal tract.31–34 Clinical subepithelial fibrosis appearing as a
white scar has been reported in the eyelids of chronic GVHD
patients.7,8 Studies have also shown a correlation between
conjunctival fibrosis and corneal epitheliopathy, suggesting
that conjunctival fibrosis likely contributes to dry eye and
ocular surface damage in GVHD.7,8 The present study used
a B10.D2 to BALB/c major MHC-matched and minor MHC-
mismatched mouse model to investigate whether this mouse
model shows features of conjunctival fibrosis as character-
ized by the presence of myofibroblasts. This mouse model
exhibits scleroderma-like features, a finding confirmed in the
present study, and the model has been extensively used to
study GVHD-associated fibrosis in various organs.24–26 The
results of the present study demonstrate that this model
indeed shows features of conjunctival fibrosis as demon-
strated by the presence of myofibroblasts. Furthermore, the
model recapitulates many other features of ocular GVHD,
including dry eye and corneal keratopathy. Interestingly,
conjunctival fibrosis was noted at 4 weeks without any
further increase in severity at 8 weeks, whereas the tear film
and keratopathy score continued to decline up to the tested
time point of 8 weeks. This trend tentatively suggests that the
conjunctival fibrosis sets in early and may contribute to the
ocular surface damage in this model that has been observed
in clinical studies.
The repair process during fibrosis typically involves the
deposition of excessive extracellular matrix which results in
replacement of normal parenchymal tissue with the hyper-
trophic scar tissue. Myofibroblast formation and prolifer-
ation are critical steps in fibrosis.9–11 Myofibroblasts are
metabolically active cells that synthesize and secrete large
quantities of extracellular matrix during fibrosis.9–11 Myofi-
broblasts also contribute to the altered mechanical proper-
ties of tissues because they express high amounts of contrac-
tile bundles of the cytoskeletal protein α-SMA. The present
study demonstrated a large number of α-SMA–positive
myofibroblasts in the orbital bulbar conjunctiva, suggesting
that GVHD-associated conjunctival fibrosis is accompanied
by myofibroblast formation. The noted increase of α-SMA
gene expression at week 4 after transplantation followed by
a decline at week 8, but a comparable number of α-SMA-
stained cells, suggests an initial proliferative phase of myofi-
broblast formation after allogeneic transplantation followed
by a stabilization phase. The resolution phase of fibrosis
is typically characterized by a decline in the myofibrob-
last number due to apoptosis and other mechanisms. Inter-
estingly, results of the current study demonstrate that the
resolution of GVHD-associated conjunctival fibrosis likely
requires more time, as a significant number of myofibrob-
lasts were still present in the conjunctiva of the GVHD mice
up to the tested time point of 8 weeks. Furthermore, a short-
ening of the eyelid was also consistently observed in the eyes
of the GVHD mice at 8 weeks. Given the detection of large
populations of myofibroblasts and their localization in the
bulbar orbital conjunctiva of the GVHD mice, it is highly
likely that the tissue contractile changes caused by these
myofibroblasts may be contributing to the noted alterations
in the eyelid architect of these GVHD mice.
GVHD is an immune condition mediated by a complex
interplay between donor immune cells and host tissue.
Immune cells of donor origin have been shown to be
present in the recipient conjunctival tissue.35 These immune
cells can release a variety of profibrotic cytokines such as
TGF-β, PDGF, and CTGF that can trigger fibroblast acti-
vation and their transdifferentiation to myofibroblasts.36–40
Further, these immune cells and activated fibroblasts also
secrete profibrotic vasoactive peptides such as endothelin
and angiotensin that can perpetuate a vicious cycle of exces-
sive wound healing and fibrosis.36–40 Activation of the RAS
and elevated levels of its effector molecule angiotensin II
have been shown to play a critical role in mediating fibrosis
in liver, skin, lung, and cardiac tissue.41–45 Ocular tissue has
been shown to express all components of the RAS.13–17,37
Overaction of the RAS has been shown to play a critical
role in conjunctival fibrosis after trabeculectomy.18,19 Results
of the present study demonstrate that GVHD-associated
myofibroblast formation was accompanied by a significant
increase in the gene and protein expression of angiotensino-
gen and ACE in the tissue around the conjunctiva. More-
over, the presence of AT1 receptors was also detected in
the eyelids of the GVHD mice, and the receptors colocal-
ized with α-SMA staining, suggesting that myofibroblasts
in conjunctival tissue express AT1 receptors. Angiotensin II
directly acting on these AT1 receptors or through increased
levels of TGF-β can promote fibroblast proliferation and
myofibroblast differentiation. Therefore, the noted increase
in local angiotensinogen and ACE activity observed in this
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study is likely to be an important contributor to the initi-
ation and perpetuation of conjunctival fibrosis and myofi-
broblast formation. Overlapping temporal kinetics between
the concomitant increase in angiotensinogen and ACE and
the increase in α-SMA expression, as noted in the present
study, further support this hypothesis.
In conclusion, results of the present study demonstrate
that GVHD-associated conjunctival fibrosis is accompanied
by myofibroblast formation and activation of the local tissue
RAS.
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